<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107674">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02028663</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_201</org_study_id>
    <nct_id>NCT02028663</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis</brief_title>
  <official_title>A Double-Blind, Randomized, Dose-finding Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the optimal dose and administration methods of
      CJ-12420 in patients with erosive esophagitis by comparing the safety and efficacy of orally
      administered CJ-12420 to esomeprazole 40mg.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cumulative healing rate of erosive esophagitis at 8-week</measure>
    <time_frame>8 week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Healing rate of erosive esophagitis at 4-week</measure>
    <time_frame>4 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Erosive Esophagitis</condition>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>CJ-12420 Amg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 volunteers will be administered CJ-12420 Amg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 Bmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 volunteers will be administered CJ-12420 Bmg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 Cmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 volunteers will be administered CJ-12420 Cmg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 volunteers will be administered Esomeprazole 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420</intervention_name>
    <description>Once daily, Oral administration</description>
    <arm_group_label>CJ-12420 Amg</arm_group_label>
    <arm_group_label>CJ-12420 Bmg</arm_group_label>
    <arm_group_label>CJ-12420 Cmg</arm_group_label>
    <other_name>Undecided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Once daily, Oral administration</description>
    <arm_group_label>Esomeprazole 40mg</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 20-70

          -  Diagnosed with Erosive Esophagitis by Esophagogastroduodenoscopy (EGD) and classified
             into LA Grade A to D within 14 days before randomization to treatment

        Exclusion Criteria:

          -  Patients who cannot undergo EGD

          -  Patients diagnosed with irritable bowel syndrome (IBS), inflammatory bowel disease
             (IBD), or suspected IBS

          -  Patients who took PPIs within 2 weeks prior to study drug administration

          -  Long-term use of nonsteroidal anti-inï¬‚ammatory drugs throughout the study

          -  Clinically significant abnormal laboratory values during screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun-Chae Jung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital and 11 others</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nam</last_name>
      <phone>02-6740-2453</phone>
    </contact>
    <investigator>
      <last_name>Hyun-Chae Jung, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>January 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P-CAB</keyword>
  <keyword>APA(Acid Pump Antagonist)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
